Kapil Dhingra, Ph.D. - Former Head, Roche Oncology Development

From 1999 to 2008, Kapil Dhingra, M.D., served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. From 1989 to 1996, Kapil was a faculty member at The University of Texas M.D. Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine 1997 to 1999, and at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Board-certified in Internal Medicine and Medical Oncology, Kapil is currently Chairman of the Board of Exosome Diagnostics and member of Boards of Directors of Advanced Accelerator Applications, Five Prime, and Autolus. He is also a member of the National Cancer Institute Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the European Organisation for Research and Treatment of Cancer. He has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics, which were all acquired by major pharmaceutical companies. Kapil founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial advances in oncology.


Kevan Shokat, Ph.D. - Chair, Department of Cellular and Molecular Pharmacology, UCSF, Professor of Chemistry, UC, Berkeley

Kevan Shokat, Ph.D., is Professor and Chair of the Department of Cellular and Molecular Pharmacology at the University of California (UC), San Francisco and Professor of Chemistry at UC, Berkeley. He is an investigator of the Howard Hughes Medical Institute and a member of the National Academy of Sciences and the Institute of Medicine. Kevan is a pioneer in the development of chemical methods for investigating cellular signal transduction pathways – with a particular focus on protein kinases and lipid kinases. His laboratory uses a combination of chemical synthesis and protein engineering to create uniquely traceable and regulatable kinases, allowing the function of more than 100 different kinases to be uncovered across all disease areas including oncology, metabolism and infectious disease.

Kevan is a founder of Intellikine (acquired by Takeda) and Cellular Genomics (acquired by Gilead), co-founder of Araxes Pharmaceuticals, eFFECTOR Therapeutics, and Mitokinin, LLC, Revolution Medicines, and a scientific advisor at Kura Oncology.  Kevan received his Ph.D. in Organic Chemistry from UC, Berkeley.


George Trainor, Ph.D. - Former head of Chemistry, Bristol Myers Squibb

Dr. Trainor brings 30 years of experience in the Biotechnology and Pharmaceutical Industries. He has expertise in overall drug discovery strategy and execution, medicinal chemistry, and the application of transformative technologies. Leading teams of over 100 scientists, he has advanced over 35 drug candidates into clinical development in a diverse spectrum of therapeutic areas including antivirals, cancer, neuroscience, and inflammation. His team provided key discovery support that enabled the successful launch of SustivaTM for HIV disease.

Dr. Trainor is a partner at BioMotiv which he joined after leaving Bristol Myers Squibb Company as Vice President of Oncology and Early Discovery Chemistry. At BMS George was responsible for all aspects of medicinal chemistry for the oncology area as well as hit-to-leads activities in support of all therapeutic areas. Prior to being merged into Bristol Myers Squibb, Dr. Trainor was Executive Director for Medicinal Chemistry at Dupont/Dupont Merck Pharmaceuticals. His key contribution from that period was the discovery and commercial development of fluorescence-tagged chain terminators for use in automated DNA sequencing. This breakthrough technology was subsequently employed in the sequencing of the human genome, and In 2011, Trainor won the American Chemical Society’s Heroes of Chemistry Award for his work on DNA sequencing.  Dr. Trainor did his undergraduate work at Stevens Institute of Technology, received his PhD in Organic Chemistry at Harvard University, and was an NIH Postdoctoral Fellow at Columbia University.